Research
Hormonal
Obesity is an independent risk factor for the onset and progression of chronic kidney disease (CKD), with visceral adiposity and fatty kidney disease serving as key pathophysiological mediators.
Maintaining a healthy weight is critical for kidney health. Excess visceral fat directly harms kidney function through inflammation and blood pressure changes. Weight management is a primary strategy to prevent or slow kidney disease.
GoodSupportsHIGH confidence
Obesity is viewed as an independent risk factor for CKD, irrespective of diabetes, hypertension, and other well-established risk factors [1].
Why this rating
Based on a comprehensive review of meta-analyses and large cohort studies (NHANES, Framingham).
Source
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Frederik Flindt Kreiner et al. · Biomedicines · 2023
DOI 10.3390/biomedicines11092498
narrative_reviewCited 33×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and reduce albuminuria, offering potential kidney protection, though their direct impact on eGFR decline in normal-functioning kidneys is not yet fully established.Good
- SGLT-2 inhibitors provide kidney protection (slowing eGFR decline, reducing albuminuria) but have limited or no impact on body weight, making them distinct from GLP-1s in treating obesity-related kidney disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →